嘉应制药(002198) - 2023 Q3 - 季度财报
JYPCJYPC(SZ:002198)2023-10-27 16:00

Financial Performance - The company's revenue for Q3 2023 was ¥119,816,763.45, a decrease of 28.58% compared to the same period last year[5] - Net profit attributable to shareholders was ¥6,657,496.96, down 51.28% year-on-year[5] - The basic earnings per share for Q3 2023 was ¥0.0131, reflecting a decline of 51.28% compared to the previous year[5] - Total operating revenue for Q3 2023 was CNY 377,231,434.03, a decrease of 9.0% compared to CNY 414,613,931.27 in the same period last year[22] - Net profit attributable to shareholders increased to CNY 95,184,667.63 from CNY 70,278,629.32, representing a growth of 35.4%[20] - The net profit for Q3 2023 was CNY 24,906,038.31, an increase of 11.8% compared to CNY 22,259,292.60 in Q3 2022[23] - Operating profit for Q3 2023 reached CNY 29,200,819.52, up from CNY 27,589,228.11 in the same period last year, reflecting a growth of 5.8%[23] - Total comprehensive income for Q3 2023 was CNY 24,906,038.31, an increase of 11.8% from CNY 22,259,292.60 in Q3 2022[24] - Basic and diluted earnings per share for Q3 2023 were both CNY 0.0491, up from CNY 0.0439 in the same quarter last year[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥829,462,181.71, a decrease of 2.03% from the end of the previous year[5] - Cash and cash equivalents as of September 30, 2023, were CNY 105,647,839.35, a decrease of 42.6% from CNY 183,858,033.90 at the beginning of the year[18] - Accounts receivable decreased to CNY 125,814,408.47 from CNY 146,026,800.41, reflecting a decline of 13.8%[18] - Inventory increased to CNY 92,041,479.17, up 12.5% from CNY 82,284,816.35 at the beginning of the year[19] - Total assets as of September 30, 2023, were CNY 829,462,181.71, down from CNY 846,650,977.26 at the beginning of the year[20] - Total liabilities decreased to CNY 77,685,566.09 from CNY 118,232,962.76, a reduction of 34.3%[20] - The company reported a total of 558,915,533.97 in current assets, slightly up from CNY 557,432,509.74 at the beginning of the year[19] - Long-term equity investments decreased to CNY 26,077,460.81 from CNY 29,378,955.16, a decline of 11.0%[19] Cash Flow - Cash flow from operating activities increased significantly by 8,632.57%, amounting to ¥52,262,283.61 year-to-date[13] - The company reported a significant increase in cash received from investment activities, rising by 223.77% year-on-year[13] - Cash flow from operating activities generated CNY 52,262,283.61, compared to CNY 598,475.67 in the previous year, showing a significant decline[26] - The company reported a net cash outflow from investing activities of CNY 130,472,478.16, compared to a net outflow of CNY 1,703,881.69 in the previous year[26] Operating Costs and Expenses - Total operating costs for Q3 2023 were CNY 349,993,013.03, down 9.3% from CNY 386,187,135.30 year-on-year[22] - The company incurred total operating expenses of CNY 413,459,740.91, a decrease from CNY 452,484,497.65 in Q3 2022[26] - Research and development expenses decreased to CNY 6,739,497.43 from CNY 7,089,552.01, indicating a reduction of 4.9%[23] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 25,945[15] - The company’s equity attributable to shareholders increased by 3.21% to ¥751,776,615.62 compared to the end of the previous year[5] - The company experienced a 258.13% increase in trading financial assets compared to the beginning of the year, totaling ¥129,739,200[10]